Jyong Biotech Ltd. cash flow statement MENS
In fiscal 2025, which ended Dec 31, 2025, Jyong Biotech Ltd. used $3.0 million of cash from operations.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
|---|---|
| Operating | |
| Depreciation and amortization |
0
|
| Operating cash flow |
-3
|
| Investing | |
| Investing cash flow |
-14
|
| Financing | |
| Short-term debt issued |
23
|
| Short-term debt repaid |
23
|
| Financing cash flow |
18
|
| Change in cash | |
| Effect of exchange rate |
-0
|
| Net change in cash |
1
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MENS (Nasdaq)
- Incorporated in
- Cayman Islands
- Headquarters
- New Taipei City
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1954488
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.